1,1-二庚基肼 | 6971-83-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1,1-二庚基肼
• 英文名称: 1,1-Diheptyl-hydrazin
• 英文别名: 1,1-Diheptylhydrazine
• CAS: 6971-83-1
• 化学式: C₁₄H₃₂N₂
• 分子量: 228.421
• InChiKey: RFXFOKUOVOSNLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  16
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  光气 、 1,1-二庚基肼 在 吡啶 作用下， 生成 1,1,5,5-Tetraheptyl-carbohydrazid
  参考文献：
  名称：

  The Anomalous Hydrogenation of Carbomethoxyhydrazones¹

  摘要：

  DOI：

  10.1021/jo01056a545
• 作为产物：
  描述：

  N-(二庚氨基)氨基甲酸甲酯 在 盐酸 作用下， 生成 1,1-二庚基肼
  参考文献：
  名称：

  The Anomalous Hydrogenation of Carbomethoxyhydrazones¹

  摘要：

  DOI：

  10.1021/jo01056a545

文献信息

• NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF
  申请人：Ochiai Hiroshi

  公开号：US20090233908A1

  公开（公告）日：2009-09-17

  A compound represented by formula (I): (wherein the symbols are the same as defined in the description), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medicinal use thereof. The compound represented by formula (I) has CXCR4 antagonistic activity. It is hence useful as, e.g., a preventive and/or therapeutic agent for CXCR4-mediated diseases such as inflammatory/immunologic diseases (e.g., rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, and rejection reactions of transplanted organs), allergic diseases, infections diseases (e.g., human immunodeficiency virus infection and acquired immunologic deficiency syndrome), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease, metabolic diseases, cancer diseases (e.g., cancer, cancer metastasis) or as an agent for regeneration therapy.

  化合物的化学式为（I）：（其中符号的定义与说明书中相同），其盐，N-氧化物，溶剂化合物或前药，以及其药用。化合物（I）具有CXCR4拮抗活性。因此，它可用作预防和/或治疗CXCR4介导疾病的药物，例如炎症/免疫疾病（例如类风湿性关节炎，关节炎，视网膜病变，肺纤维化和移植器官的排斥反应），过敏性疾病，感染性疾病（例如人类免疫缺陷病毒感染和获得性免疫缺陷综合症），心理神经疾病，脑部疾病，心血管疾病，代谢性疾病，癌症（例如癌症，癌症转移）或再生治疗剂。
• Compound Containing Basic Group and Use Thereof
  申请人：Kokubo Masaya

  公开号：US20080009495A1

  公开（公告）日：2008-01-10

  The present invention relates to a compound represented by formula (I-0): wherein symbols in formula have the same meanings as described in the present specification, a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof, and medical use thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

  本发明涉及一种由式（I-0）表示的化合物：其中，式中的符号与本说明书中所述的意义相同，其盐，N-氧化物或溶剂化物或其前药，以及其医学用途。本发明的化合物具有对CXCR4的拮抗活性，因此可用作预防和/或治疗CXCR4介导的疾病的药物，例如，炎症和免疫性疾病（例如，类风湿性关节炎，关节炎，视网膜病变，肺纤维化，移植器官排斥等），过敏性疾病，感染（例如，人类免疫缺陷病毒感染，获得性免疫缺陷综合症等），精神神经疾病，脑部疾病，心血管疾病，代谢性疾病和癌症性疾病（例如，癌症，癌症转移等），或作为再生疗法的药物。
• CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF
  申请人：Kokubo Masaya

  公开号：US20120207765A1

  公开（公告）日：2012-08-16

  A compound represented by general formula (I): a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease (for example, arteriosclerosis, myocardial infarction, stenocardia, cerebral infarction, chronic arterial occlusive disease, etc.), metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and/or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.

  通式（I）所代表的化合物：其盐、溶剂化物或前药物，其中所有符号均如规范中所定义，具有对CXCR4的拮抗活性，因此可用作预防和/或治疗CXCR4介导的疾病，例如炎症和免疫性疾病（例如类风湿性关节炎、关节炎、系统性红斑狼疮、视网膜病变、黄斑变性、肺纤维化、移植器官排斥等）、过敏性疾病、感染（例如人类免疫缺陷病毒感染、获得性免疫缺陷综合症等）、心理神经疾病、脑部疾病、心脏/血管疾病（例如动脉硬化、心肌梗死、心绞痛、脑梗死、慢性动脉闭塞性疾病等）、代谢性疾病和癌症性疾病（例如癌症、癌症转移等），是用于癌症性疾病或感染的预防和/或治疗剂，或再生疗法的剂。
• Expedient Tandem Dehydrogenative Alkylation and Cyclization Reactions Under Mn(I)-Catalysis
  作者：Reshma Babu、Subarna S Padhy、Ganesan Sivakumar、Balaraman Ekambaram

  DOI：10.1039/d3cy00009e

  日期：——

  coherent and robust catalytic systems based on earth-abundant transition metals is essential; however, it is extremely challenging. Herein, an expedient divergence strategy for tandem dehydrogenative alkylation and cyclization reactions of hydrazides is reported under manganese catalysis. Using abundantly available alcohols (including MeOH, EtOH) and earth-abundant metal catalysts with water as a sole by-product

  可持续的化学生产从根本上需要新型催化剂和催化技术。基于地球上丰富的过渡金属开发连贯而强大的催化系统至关重要；然而，这是极具挑战性的。在此，报道了在锰催化下酰肼的串联脱氢烷基化和环化反应的权宜发散策略。使用大量可用的醇类（包括甲醇、乙醇）和地球上储量丰富的金属催化剂，水作为唯一的副产品，使目前的战略更具可持续性和可负担性。有趣的是，不对称的选择性氘掺入也是首次出现。几个选择性键激活/形成反应通过胺-酰胺金属-配体合作依次发生。
• Expandable and curable polyester composition and method for making same
  申请人：UNIROYAL, INC.

  公开号：EP0083173A1

  公开（公告）日：1983-07-06

  An expandable and curable polyester composition comprising a mixture of a liquid, ethylenically unsaturated polyester resin composition; a peroxide; an organometallic promotor; and a dialkyl or trialkyl hydrazine is disclosed. In addition, a method for forming said expanded and cured polyester resin composition, and the product formed in accordance with said method, an expanded and cured polyester resin composition, is taught.

  本发明公开了一种可膨胀固化的聚酯组合物，该组合物包含一种液态乙烯基不饱和聚酯树脂组合物、一种过氧化物、一种有机金属促进剂和一种二烷基或三烷基肼的混合物。 此外，还教导了一种形成所述膨胀固化聚酯树脂组合物的方法，以及根据所述方法形成的产品--膨胀固化聚酯树脂组合物。